N04BA02 • levodopa + carbidopa • Nervous system | Dopaminergic agents | Dopa and dopa derivatives
Levodopa + Carbidopa is a combination medication used in the treatment of Parkinson's disease and parkinsonian syndromes. Levodopa is a precursor of dopamine, which helps compensate for the dopamine deficiency in the brain characteristic of these conditions. Carbidopa is a peripheral decarboxylase inhibitor that prevents levodopa from being converted into dopamine outside the brain, increasing the amount of levodopa that reaches the brain and reducing side effects such as nausea.
This combination is effective in alleviating symptoms such as tremors, muscle rigidity, bradykinesia (slowness of movement), and balance difficulties. The medication is usually administered in gradually adjusted doses to minimize side effects and optimize benefits.
Side effects may include nausea, dizziness, drowsiness, motor fluctuations (such as 'on-off' phenomena), or, in rare cases, hallucinations and mood changes. It is important to take the medication as prescribed by a doctor, with regular monitoring to adjust doses based on the progression of the disease.
Substance: levodopa + carbidopa
Date of last drug list: 01-06-2021
Commercial code: W43479001
Pharmaceutical form: internal gel
Quantity: 7
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).